Acelyrin (SLRN) Stock Forecast & Price Target

$5.68

-0.22 (-3.73%)

(As of 10/31/2024 ET)

Acelyrin - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 6 Analyst Ratings

Sell
0

Hold
3

Buy
3

Based on 6 Wall Street analysts who have issued ratings for Acelyrin in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 3 have given a hold rating, and 3 have given a buy rating for SLRN.

Consensus Price Target

$11.17
96.60% Upside

According to the 6 analysts' twelve-month price targets for Acelyrin, the average price target is $11.17. The highest price target for SLRN is $20.00, while the lowest price target for SLRN is $6.00. The average price target represents a forecasted upside of 96.60% from the current price of $5.68.

Get the Latest News and Ratings for SLRN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Acelyrin and its competitors.

SLRN Analyst Ratings Over Time

Type	Current Forecast 11/1/23 to 10/31/24	1 Month Ago 10/2/23 to 10/1/24	3 Months Ago 8/3/23 to 8/2/24	1 Year Ago 11/1/22 to 11/1/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	4 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$11.17	$10.83	$12.80	$37.00
Forecasted Upside	96.60% Upside	112.84% Upside	132.52% Upside	305.26% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (Ad)

Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.

Click here to see it because it’s a SHOCKER…

SLRN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SLRN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Acelyrin Stock vs. The Competition

Type	Acelyrin	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	107.17% Upside	15,773.04% Upside	10.09% Upside
News Sentiment Rating	Positive News See Recent SLRN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/16/2024	Wells Fargo & Company 3 of 5 stars	D. Archila Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$13.00 ➝ $15.00	+153.81%
8/19/2024	Morgan Stanley 3 of 5 stars		Lower Target	Equal Weight ➝ Equal Weight	$13.00 ➝ $6.00	+47.78%
8/14/2024	Piper Sandler 2 of 5 stars		Lower Target	Overweight ➝ Overweight	$68.00 ➝ $20.00	+401.25%
8/14/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Bodnar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$18.00 ➝ $6.00	+26.05%
12/8/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$8.00	+11.73%
11/28/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$15.00 ➝ $12.00	+100.00%
5/30/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:29 PM ET.

SLRN Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Acelyrin is $11.17, with a high forecast of $20.00 and a low forecast of $6.00.
: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acelyrin in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SLRN shares.
: According to analysts, Acelyrin's stock has a predicted upside of 96.60% based on their 12-month stock forecasts.
: Over the previous 90 days, Acelyrin's stock had 1 downgrade by analysts.
: Acelyrin has been rated by research analysts at HC Wainwright, Morgan Stanley, Piper Sandler, and Wells Fargo & Company in the past 90 days.
: Analysts like Acelyrin less than other "medical" companies. The consensus rating score for Acelyrin is 2.50 while the average consensus rating score for "medical" companies is 2.79. Learn more on how SLRN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

The most serious warning of my career (Ad)

With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election.

Click here now to grab your seat now.

This page (NASDAQ:SLRN) was last updated on 10/31/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acelyrin (SLRN) Stock Forecast & Price Target